Albireo Pharma (NASDAQ:ALBO) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, September 18th.
A number of other research firms also recently weighed in on ALBO. Wedbush reissued an “outperform” rating and set a $69.00 target price on shares of Albireo Pharma in a research report on Tuesday, June 12th. Zacks Investment Research downgraded Albireo Pharma from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. Finally, Cowen restated a “buy” rating on shares of Albireo Pharma in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $59.40.
Albireo Pharma stock traded up $0.42 during mid-day trading on Tuesday, hitting $26.01. 25,924 shares of the company’s stock were exchanged, compared to its average volume of 69,771. The company has a market capitalization of $394.53 million, a price-to-earnings ratio of -8.26 and a beta of 1.45. Albireo Pharma has a 1-year low of $21.25 and a 1-year high of $39.87.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.24). The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $2.00 million. Equities research analysts forecast that Albireo Pharma will post -3.39 EPS for the current year.
In other news, insider Ronald Harold Wilfred Cooper bought 788 shares of the business’s stock in a transaction dated Tuesday, August 14th. The stock was bought at an average price of $31.85 per share, for a total transaction of $25,097.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Hartwell J M Limited Partnership raised its position in Albireo Pharma by 32.7% in the 2nd quarter. Hartwell J M Limited Partnership now owns 13,400 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 3,300 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in Albireo Pharma during the 2nd quarter worth $118,000. Acadian Asset Management LLC acquired a new stake in Albireo Pharma during the 2nd quarter worth $165,000. MetLife Investment Advisors LLC acquired a new stake in Albireo Pharma during the 2nd quarter worth $167,000. Finally, Northern Trust Corp grew its holdings in Albireo Pharma by 60.3% during the 1st quarter. Northern Trust Corp now owns 15,766 shares of the biopharmaceutical company’s stock worth $513,000 after acquiring an additional 5,932 shares during the period. Hedge funds and other institutional investors own 63.41% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.